[{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"710fbbdc-56f1-402d-9817-416d903d4d64","acronym":"SUPβORT","url":"https://clinicaltrials.gov/study/NCT07000305","created_at":"2025-06-07T14:45:31.114Z","updated_at":"2025-06-07T14:45:31.114Z","phase":"Phase 2","brief_title":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","source_id_and_acronym":"NCT07000305 - SUPβORT","lead_sponsor":"Tao Zhang","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2028","study_completion_date":" 05/20/2028","last_update_posted":"2025-06-02"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"087d5cdf-3bbf-47a4-a244-528df8b9dbc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06833866","created_at":"2025-02-25T14:13:40.666Z","updated_at":"2025-02-25T14:13:40.666Z","phase":"Phase 1","brief_title":"Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06833866","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/04/2024","start_date":" 12/04/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-19"},{"id":"3c5d0961-29c6-44c5-9f18-012dc3b4ae3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06504381","created_at":"2025-02-25T14:04:35.935Z","updated_at":"2025-02-25T14:04:35.935Z","phase":"Phase 1/2","brief_title":"DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma","source_id_and_acronym":"NCT06504381","lead_sponsor":"University of California, San Francisco","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/08/2025","start_date":" 01/08/2025","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2042","study_completion_date":" 01/31/2042","last_update_posted":"2025-02-19"},{"id":"d4706b4b-87ff-43ad-a128-bb849b25cb0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01972919","created_at":"2021-01-18T08:58:44.421Z","updated_at":"2025-02-25T15:32:57.905Z","phase":"Phase 2","brief_title":"MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01972919","lead_sponsor":"Medical College of Wisconsin","biomarkers":" CEACAM5","pipe":" | ","alterations":" SMAD4 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMAD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/10/2015","start_date":" 12/10/2015","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-10"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"8a36dc46-7e94-43f5-8360-2cd36c81ca39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034251","created_at":"2021-01-18T19:47:54.419Z","updated_at":"2025-02-25T17:00:07.598Z","phase":"Phase 2","brief_title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","source_id_and_acronym":"NCT04034251","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 02/25/2023","primary_completion_date":" 02/25/2023","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2025-02-03"},{"id":"acc48af8-087d-49b6-a58a-47451b735f6f","acronym":"COMBIGaPP","url":"https://clinicaltrials.gov/study/NCT06782022","created_at":"2025-02-25T20:11:02.556Z","updated_at":"2025-02-25T20:11:02.556Z","phase":"Phase 2","brief_title":"DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients","source_id_and_acronym":"NCT06782022 - COMBIGaPP","lead_sponsor":"Jan Gerard Maring","biomarkers":" DPYD","pipe":"","alterations":" ","tags":["DPYD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 02/02/2020","start_date":" 02/02/2020","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2025-01-17"},{"id":"cd1a66a4-5dbf-4a32-901c-c7c94f2f942d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06576921","created_at":"2025-02-26T06:54:16.281Z","updated_at":"2025-02-26T06:54:16.281Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","source_id_and_acronym":"NCT06576921","lead_sponsor":"Xijing Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • oxaliplatin • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-01-13"},{"id":"1915f7a6-8053-43df-93b9-e85775f2fa36","acronym":"","url":"https://clinicaltrials.gov/study/NCT06765252","created_at":"2025-02-26T07:06:55.090Z","updated_at":"2025-02-26T07:06:55.090Z","phase":"","brief_title":"Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients","source_id_and_acronym":"NCT06765252","lead_sponsor":"Ain Shams University","biomarkers":" CES1","pipe":"","alterations":" ","tags":["CES1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-01-09"},{"id":"1573c9ba-1ace-4553-8cab-adbfb67bb630","acronym":"OXEL","url":"https://clinicaltrials.gov/study/NCT03487666","created_at":"2021-01-18T17:10:41.220Z","updated_at":"2025-02-25T14:38:14.167Z","phase":"Phase 2","brief_title":"OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease","source_id_and_acronym":"NCT03487666 - OXEL","lead_sponsor":"Georgetown University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 11/03/2021","primary_completion_date":" 11/03/2021","study_txt":" Completion: 05/02/2024","study_completion_date":" 05/02/2024","last_update_posted":"2024-12-03"},{"id":"1455a292-12e3-4ee4-837b-54ea7dad02d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06533384","created_at":"2025-02-27T07:58:59.217Z","updated_at":"2025-02-27T07:58:59.217Z","phase":"Phase 3","brief_title":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","source_id_and_acronym":"NCT06533384","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-11-04"},{"id":"d131c943-6eec-4c31-8917-631846af0eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06090994","created_at":"2025-02-27T18:34:32.567Z","updated_at":"2025-02-27T18:34:32.567Z","phase":"Phase 4","brief_title":"Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy","source_id_and_acronym":"NCT06090994","lead_sponsor":"Fudan University","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 756","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-08-20"},{"id":"8db1acf5-a900-4cd5-833c-3f33dc56134c","acronym":"IRIMAD","url":"https://clinicaltrials.gov/study/NCT06501482","created_at":"2025-02-26T14:30:19.761Z","updated_at":"2025-02-26T14:30:19.761Z","phase":"Phase 3","brief_title":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","source_id_and_acronym":"NCT06501482 - IRIMAD","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2024-07-15"},{"id":"07559a56-04b6-451e-84a1-341907a657e2","acronym":"LOGiC","url":"https://clinicaltrials.gov/study/NCT00680901","created_at":"2021-01-18T02:32:43.490Z","updated_at":"2024-07-02T16:34:26.181Z","phase":"Phase 3","brief_title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","source_id_and_acronym":"NCT00680901 - LOGiC","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 06/04/2008","start_date":" 06/04/2008","primary_txt":" Primary completion: 09/24/2012","primary_completion_date":" 09/24/2012","study_txt":" Completion: 01/22/2025","study_completion_date":" 01/22/2025","last_update_posted":"2024-06-13"},{"id":"456e64a7-c785-425d-86d5-0f68c14266f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105684","created_at":"2023-10-30T16:12:24.791Z","updated_at":"2024-07-02T16:35:05.176Z","phase":"Phase 2","brief_title":"Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT06105684","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-08"},{"id":"5d8ffb56-1901-4937-a8c8-b205ac4fa2e1","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT05693766","created_at":"2023-01-23T16:00:10.585Z","updated_at":"2024-07-02T16:35:08.227Z","phase":"Phase 2","brief_title":"Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort","source_id_and_acronym":"NCT05693766 - INSIGHT","lead_sponsor":"Sonya Reid","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/11/2023","start_date":" 09/11/2023","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2037","study_completion_date":" 08/31/2037","last_update_posted":"2024-04-23"},{"id":"587353e8-69d4-43ef-a2e4-48bd6a9a08e3","acronym":"NuTide:302","url":"https://clinicaltrials.gov/study/NCT03428958","created_at":"2021-01-19T15:31:48.117Z","updated_at":"2024-07-02T16:35:11.599Z","phase":"Phase 1/2","brief_title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","source_id_and_acronym":"NCT03428958 - NuTide:302","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-03"},{"id":"6adec79d-70e3-4577-bae0-5f0e8b153dfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678257","created_at":"2023-01-10T14:58:55.263Z","updated_at":"2024-07-02T16:35:11.773Z","phase":"Phase 2","brief_title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05678257","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF • UGT1A1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • UGT1A1*1*1","tags":["KRAS • BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-03"},{"id":"adb47411-e4ca-44c0-af22-a98798c3a97a","acronym":"EC-CRT-007","url":"https://clinicaltrials.gov/study/NCT06187597","created_at":"2024-01-02T14:16:57.201Z","updated_at":"2024-07-02T16:35:15.221Z","phase":"Phase 2","brief_title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","source_id_and_acronym":"NCT06187597 - EC-CRT-007","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40","pipe":"","alterations":" ","tags":["IL6 • CTLA4 • IL2RA • NCAM1 • CD68 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-03-12"},{"id":"38f7df43-6d39-4c5a-b6a7-8f82347e32a1","acronym":"HELEN-008","url":"https://clinicaltrials.gov/study/NCT05063136","created_at":"2021-09-30T22:53:06.634Z","updated_at":"2024-07-02T16:35:17.657Z","phase":"Phase 3","brief_title":"Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer","source_id_and_acronym":"NCT05063136 - HELEN-008","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 1979","initiation":"Initiation: 09/28/2021","start_date":" 09/28/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-02-26"},{"id":"a4358a55-bb2f-45d7-afee-83bf08384f86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04768426","created_at":"2021-02-24T13:59:52.857Z","updated_at":"2024-07-02T16:35:18.136Z","phase":"Phase 2","brief_title":"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer","source_id_and_acronym":"NCT04768426","lead_sponsor":"Stanford University","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-02-22"}]